Michael Sumner, MB BS, MBA
Chief Medical Officer and Head of Development
Dr. Sumner is responsible for setting the development strategy and overseeing the execution of the company’s DNA Medicine portfolio. Dr. Sumner previously served as CMO of Orexo AB and held numerous European- and US-based leadership roles at Novartis Pharmaceuticals, Aventis Behring, Novo Nordisk and Shire Pharmaceuticals. Dr. Sumner brings over 30 years of extensive pharmaceutical, medical and clinical experience driving numerous late-stage product approvals and supporting successful commercial products on a global basis across multiple therapeutic areas.
Dr. Sumner received his medical degree from the University of London, is a member of the Royal College of Physicians, and holds a Master of Business Administration from Henley Management College, UK.
By harnessing the strengths of in vivo protein production, I believe we can reshape treatment paradigms and bring transformative treatment options to patients who need them most.”